Skip to main content
ClinicoEconomics and Outcomes Research: CEOR logoLink to ClinicoEconomics and Outcomes Research: CEOR
. 2026 Nov 10;18:637548. doi: 10.2147/CEOR.S637548

Cost-Effectiveness Analysis of Lebrikizumab versus Dupilumab for Patients with Severe Atopic Dermatitis in Austria

Bernhard Schwarz 1, Laia Solé-Feu 2, Yannick Walzer 3,✉, Bülent Akmaz 2
PMCID: PMC13769249  PMID: 43034756

Abstract

Introduction

Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant economic burden. This study evaluated the cost-effectiveness of lebrikizumab compared to dupilumab for adults and adolescents with severe AD from an Austrian healthcare payer’s perspective.

Methods

A cost-effectiveness analysis, based on the NICE assessment’s TA986 model, was conducted, comprising a decision tree for the first year and a Markov model for long-term outcomes. The analysis adopted a healthcare system perspective, discount rate (3%) and applied Austrian-specific data, costs and quality of life measures. Two scenarios assessed the robustness of the base case analysis.

Results

The base case analysis showed lebrikizumab was associated with lower total costs (€128,961 vs €133,870) and slightly lower QALYs (16.53 vs 16.56) compared to dupilumab over a lifetime horizon. The primary driver of cost savings was lower drug acquisition costs for lebrikizumab (-€5,349). Scenario analyses with different economic and clinical data demonstrated cost-effectiveness for lebrikizumab.

Discussion

This economic evaluation suggests lebrikizumab is a potential cost-saving alternative to dupilumab based on the base case analysis of this health economic model for severe AD treatment in Austria, with comparable clinical efficacy. Consequently, lebrikizumab has been reimbursed in Austria since January 2025 as the second biological therapeutic option alongside dupilumab, following national pricing and reimbursement rules.

Keywords: atopic dermatitis, biologics, Cost-effectiveness-analysis (CEA), dupilumab, lebrikizumab

Introduction

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by intensely pruritic, eczematous lesions and impaired skin barrier function.1,2 The prevalence is estimated at approximately 20% in children and 2–7% in adults worldwide.3 The disease course is typically marked by recurrent flares and remissions, with complete resolution being rare. The pathogenesis of AD is complex, involving genetic factors, environmental influences, and immune system dysregulation, particularly an overactivation of T helper 2 cells and elevated levels of proinflammatory cytokines such as interleukin-4 and interleukin-13.4

Standard therapy for AD follows a stepwise approach, contingent upon disease severity. A regular basic therapy with emollients is recommended to improve skin barrier function. For mild to moderate AD, topical glucocorticosteroids or topical calcineurin inhibitors are employed. These therapies aim to reduce inflammation, alleviate pruritus, and stabilize the skin barrier.4–6

For moderate-to-severe AD that does not adequately respond to topical therapies, systemic treatments are recommended. According to current European and German guideline, cyclosporine A is the first-line choice for systemic immunosuppression. Other approved options include methotrexate, azathioprine, and mycophenolate mofetil. While these therapies can significantly reduce disease activity, they are associated with potential adverse effects and are often unsuitable for long-term use.4,6

In recent years, targeted biologics have substantially expanded treatment options for moderate-to-severe AD. As of January 1, 2025, Lebrikizumab has been granted reimbursement by the national social health insurance agency Federation of Austrian Social Insurances (Dachverband der österreichischen Sozialversicherungsträgern, DV), in accordance with established pricing and reimbursement rules. It is now available as the second biological therapeutic option alongside Dupilumab. Tralokinumab, though listed, has not yet secured reimbursement. The newest addition to this category, Nemolizumab, has recently been listed and is currently in the process of applying for reimbursement, as evidenced by its red box designation (as of July 2025). Dupilumab, a monoclonal antibody against the interleukin-4 receptor, was the first approved biologic for this indication. Furthermore, dupilumab is the most commonly used drug in the treatment of AD.7 It was therefore selected as the relevant comparator for the Austrian setting. Simpson et al,8 demonstrated the efficacy and safety of dupilumab in two Phase 3 studies (SOLO 1 and SOLO 2) in adult patients with moderate-to-severe AD across Europe including Austria as well. After 16 weeks, significantly more patients receiving dupilumab achieved improvement in Investigator’s Global Assessment (IGA) and Eczema Area and Severity Index (EASI) compared to placebo.8

Lebrikizumab, a newer biologic, is a monoclonal antibody specifically inhibiting interleukin-13. Silverberg et al,3 investigated the efficacy and safety of lebrikizumab as monotherapy in two phase 3 studies (ADvocate 1 and 2) in adolescents and adults with moderate-to-severe AD as well. After 16 weeks, lebrikizumab led to significant improvements in skin clearance, pruritus and itch-related sleep loss compared with placebo.3 In addition, Simpson et al,9 investigated lebrikizumab in combination with topical corticosteroids in the phase 3 trial ADhere. Results showed that lebrikizumab led to significant improvements in disease activity, pruritus, and quality of life compared to placebo plus topical corticosteroids after 16 weeks.9

The clinical comparability of lebrikizumab and dupilumab has been confirmed within 16 weeks of treatment in several studies. Systematic reviews and meta-analyses by Pereyra-Rodriguez et al,10 and Drucker et al,11 compared the efficacy and safety of various biologics and systemic treatments for moderate-to-severe atopic dermatitis. Recent data for 52 weeks from Rand et al,12 further indicate the absence of a statistically significant difference between both medications rather than formally demonstrated equivalence, which is relevant both clinically and from a health economic perspective.12

In this context, Austrian legal pricing framework (§ 351c Abs. 9 Austrian Social Security Act (Allgemeines Sozialversicherungsgesetz, ASVG) stipulates that new, therapeutically equivalent drugs should be priced lower than existing therapies. This regulatory provision aims to promote competition and improve cost efficiency in the healthcare system.13 To empirically demonstrate the price advantages of lebrikizumab over dupilumab and evaluate its economic viability, a comprehensive economic analysis is necessary, which is commonly obligated by national payer authorities.

This economic analysis aims not only to demonstrate robust foundation for healthcare decision-makers to approve for local reimbursement to the national Austrian reimbursement system. It is designed to facilitate an assessment of the cost-effectiveness and optimal utilization of novel biologicals in the treatment of moderate-to-severe atopic dermatitis (according to the SmPC). In order to achieve this objective, an indirect comparison has been executed from the perspective of the Austrian healthcare system. Taking into account the current regulatory framework13 in Austria only severe AD patients are being reimbursed and hence also evaluated within this assessment. Throughout this article, “moderate-to-severe AD” refers to the populations enrolled in the pivotal trials and indirect comparisons that inform the efficacy inputs, whereas “severe AD” refers to the Austrian reimbursement population to which the economic evaluation applies.

Methods

A cost-effectiveness model based on the UK NICE accepted model within assessment TA986, was adapted for the Austrian context14 to evaluate the economic impact of lebrikizumab compared to dupilumab for the treatment of severe atopic dermatitis (AD) in the public Austrian health care setting. The model structure comprises two main components: a decision tree for the first year of treatment and a Markov model for long-term modelling starting from year 2 onwards. These components work in tandem to capture both the induction and maintenance phases of treatment, as well as the long-term outcomes and costs associated with AD management.14,15 The patients’ characteristics correspond to those of the modelled population according to the phase 3 Lebrikizumab ADvocate studies 1 and 2,3 reported in Table 1.

Table 1.

Baseline Characteristics of the Model Population in the Pool of ADvocate1 and 2

Parameter Value Source
Age (years), mean (SD) 34 (15.24) Silverberg et al, 2023.3
Adults (≥18 years), n (%) 292/331 (88%)
Adolescents (12–18 years) 12%
Female, n (%) 156/331 (47%)

In the decision tree (Figure 1), which represents the first year of treatment, all patients begin with either lebrikizumab (intervention) or dupilumab (comparator) as their first-line therapy. This initial treatment period lasts for 16 weeks, after which a critical assessment of treatment response occurs. Response is defined for different clinical endpoints like EASI 75, IGA 0/1 or the combined endpoint EASI 50 and DLQI 4 points. Patients who respond to the treatment continue with their initial therapy until week 52, while non-responders discontinue and switch to best supportive care (BSC). It’s important to note that even among responders, there is a possibility of losing response or discontinuing treatment for various reasons between weeks 16 and 52. In such cases, these patients transition to the long-term Markov model and receive either a comparator or BSC.

Figure 1.

A decision tree of first year treatment response at 16 weeks and pathways to 52 weeks outcomes. Decision tree from baseline to 52 weeks: patients with moderate-to-severe AD are split at 16 weeks into responders, who either maintain response (Markov “Response” state) or lose it (Markov “Subsequent treatment” phase), and non-responders, who discontinue and receive a comparator or BSC (Markov “Subsequent treatment” phase).

Modelled decision tree for the first year of treatment (short-term model).

The Markov model (Figure 2), which begins at the start of year 2, operates on annual cycles and distinguishes between two primary health states: responders and non-responders. This simplification was necessary due to the lack of sufficient data on partial response at the time of model development. Patients who maintain their response at the beginning of year 2 remain in the responder health state until they either lose response or discontinue for other reasons (termed as all-cause discontinuation). Those who lose response or discontinue treatment transition to the non-responder state and commence BSC in the subsequent Markov cycle.

Figure 2.

A Markov state transition diagram for initial and subsequent treatment with response, non-response, partial response and death.

Markov model applied from the 2nd year of treatment (long-term model).

Within the model, death can occur at any time from any state. As AD adds no excess mortality, deaths follow age/sex-specific population rates, yielding realistic survival. The base case analysis was conducted over a lifetime horizon of 66 annual cycles, from a mean baseline age of 34 years until age 100. This corresponded to an average of 46.6 undiscounted life-years, or 25.0 discounted life-years at an annual discount rate of 3%. The efficacy assumptions underpinning the model are based on robust clinical evidence. Lebrikizumab and dupilumab have shown comparable efficacy and safety profiles in the treatment of moderate-to-severe AD. No statistically significant difference between the two treatments was found in network meta-analyses for the 16-week induction phase16 and a matched adjusted indirect comparison for long-term therapy up to 52 weeks.12 As the corresponding confidence intervals included the null value throughout and no pre-specified equivalence margin was applied, this reflects an absence of a demonstrated difference rather than proven therapeutic equivalence. The model therefore retains the treatment-specific point estimates of response derived from these analyses as inputs (Table 2), applies identical discontinuation rates to both treatments thereafter, and holds health-state utility values constant across treatments. The resulting small numerical differences in modelled QALYs reflect the propagation of these point estimates over the lifetime horizon rather than an independently established difference in clinical effectiveness.

Table 2.

Clinical Input Data

Observation Lebrikizumab Dupilumab Best-Supportive-Care (BSC) (Second-Line Systemic Treatment)
Response EASI 75 46.6% = ~47%(46.8%) 49.0% = ~49%(49.17%) 20.0%
Response IGA (0, 1) 31.4 (31%) 31.8 (32%) 20.0%
Source Network meta-analysis.16 16-week Pooled placebo data from Measure Up 1, 2 Guttman-Yassky et al 202117 and NICE, 2021, TA681.18
Injection site reaction 1.60% 10.97% 0%
Allergic conjunctivitis 2.50% 3.01% 0.33%
Infectious conjunctivitis 7.50% 4.30% 1.65%
Oral herpes 2.30% 3.66% 1.65%
Upper respiratory tract infection 0.20% 2.80% 6.93%
Acne 0.20% 0.00% 1.98%
Source Simpson et al, 20168 and Silverberg et al, 2023.3 Reich et al, 202119
Proportion of patients experiencing flare 16% 18% 33%
Duration of follow-up (weeks) 36 16 16
Source Pooled ADvocate 1 and 2 data, observed during week 16–52 (Silverberg et al, 2023.3 16-week data from SOLO1 & SOLO2, (NICE, 2018, TA534.20) 16-week placebo data from AD-UP (Reich et al, 2021.19

Clinical Data

All relevant clinical data are displayed in Table 2. Response probabilities were determined through a network meta-analysis (NMA) of the clinical outcomes EASI 50, EASI 75, EASI 90 and IGA 0/1,16 calculated relative to the baseline response to BSC, which is considered representative of week 16 after treatment initiation. In the base case, this baseline was 20.0%, based on pooled placebo data from the second-line systemic treatment subgroup of Measure Up 1 and 2.17

Because EASI 50 + DLQI≥4 was not reported in the pivotal lebrikizumab trials and was not consistently reported across comparators, it could not be synthesised in the NMA. EASI 75 odds ratios versus placebo were therefore applied to the baseline (BSC) EASI 50 + DLQI≥4 probability for both treatments, converting the EASI 75 relative treatment effect into absolute week-16 response probabilities of 63.5% (lebrikizumab) and 65.7% (dupilumab). This approach mirrors the one accepted in NICE TA986 for lebrikizumab, where the company considered EASI 75 to have the closest relative response to the composite endpoint. The EAG questioned the similarity between the endpoints but acknowledged the general approach as reasonable in the absence of further data; clinical experts noted that EASI 75 is harder to achieve than the composite outcome but expected a similar relative treatment effect, since a DLQI reduction closely tracks the EASI score.21 The Committee ultimately considered this approach appropriate when composite endpoint data were unavailable. EASI 75 and IGA 0/1 were applied directly as alternative response definitions in two scenario analyses, using baseline placebo responses from the ADvocate 1 and 2 subgroup with prior systemic treatment (9.2% and 3.9%, respectively).

In line with the NICE committee’s preference from the lebrikizumab appraisal, a short-term discontinuation rate of 3.9% for lebrikizumab and dupilumab between weeks 16 and 52 is assumed, and the model explicitly applies this rate to responders as well to reflect the real-world likelihood of treatment cessation despite an initial response.21 From year 2 onward, an annual loss-of-response or discontinuation probability was used in the Markov model. As no separate long-term data existed for each drug, an identical rate, averaged from the reference NICE model,21 was applied to both arms, in line with the assumed long-term equivalence.

The model also considers adverse events (AEs) based on reports from 16-week studies.3,8,19 For the initial 16-week period, AE rates are directly extracted from study results. For subsequent modelling periods, including up to week 52 and from year 2 onwards, these AE rates are extrapolated to provide a comprehensive view of the safety profile over the entire treatment duration.

An important aspect of AD management captured in the model is the occurrence of flares - acute exacerbations of the disease. The model acknowledges that the probability of flares may differ between treatment alternatives. However, it assumes that the treatment of flares, once they occur, is consistent across all treatment options, involving the same acute therapy. The probabilities of flares used in the model are derived from the frequency of rescue medication prescriptions observed in clinical studies, following recommendations from UK NICE (TA534 and TA681).18–20 While flare probabilities were observed over different follow-up periods (36 weeks for lebrikizumab; 16 weeks for dupilumab/BSC), cumulative probabilities were converted to a constant weekly rate and re-aggregated to the relevant model timeframe (weekly in the decision tree, annualized in the Markov model). The same constant-hazard approach extrapolated the 16-week adverse-event rates to week 52 and the long-term model.

Cost Data

In terms of costs, the model exclusively uses Austrian tariffs and prices from January 2024 to ensure relevance and accuracy for the Austrian healthcare context. Hospital services are costed using LKF inpatient and outpatient tariffs, while outpatient sector services are based on ÖGK Vienna tariffs. Medication costs are derived from reimbursement prices listed in the EKO as of January 1, 2026.22 The model calculates drug costs for lebrikizumab and dupilumab based on their respective dosing regimens and pack prices. Additionally, it incorporates costs for concomitant therapy, healthcare resource use, management of adverse events, and treatment of flares to provide a comprehensive economic assessment. Details of inputted cost data are available in the supplement with drug acquisition costs (Supplement C), costs of accompanying therapy (Supplement D), unit costs (Supplement E and F) and the level of consumption of healthcare resources separated for adults and adolescents (Supplement G and H).

The perspective adopted in the model aligns with the requirements set forth in §25 Abs. 1 of the Procedural Rules for the Publication of the Reimbursement Code in Austria.23 Notably, indirect costs are not considered in this analysis. This assumes that the same indirect costs are administered in both arms.

In the base case scenario, costs are discounted at a rate of 3%. Two scenario analyses were performed to account for uncertainties and verify the robustness of the model results. These analyses focused on the different endpoints EASI75 and IGA 0/1 and aimed to provide a holistic view of the most important endpoints in the field of AD and to capture the effects of model uncertainties on the final cost-effectiveness results. A probabilistic sensitivity analysis was not performed, as the assumed efficacy/safety equivalence leaves no incremental-effectiveness distribution to combine with the cost distributions.

Results

The analysis indicates that lebrikizumab incurs a lower overall cost than dupilumab and cost-effectiveness in the long run. The primary distinction pertains to the reduced cost associated with lebrikizumab, while other cost categories, including health status, adverse effects and flare-ups, remain comparable.

Base Case Analysis

The base case analysis was conducted over a lifetime horizon (average 25 years) with a 3% annual discount rate for both costs and outcomes. The model assumed that all patients were treated without topical corticosteroids (monotherapy) for both Lebrikizumab and Dupilumab. The analysis was based on patients aged 12 years and older with a body weight of at least 40 kg, who had moderate to severe atopic dermatitis and for whom systemic treatments were not sufficiently effective, not tolerated, or contraindicated. The primary outcomes of the base case analysis for lebrikizumab and dupilumab are presented in Table 3. Efficacy inputs for lebrikizumab and dupilumab (Table 2) showed no statistically significant difference at week 16, although the underlying point estimates differed numerically. Total costs differed meaningfully between treatments, with lebrikizumab associated with lower overall costs than dupilumab.

Table 3.

Primary Clinical and Economic Outcomes of the Base Case Analysis

Parameter Lebrikizumab Dupilumab Incremental
Total costs (€) €128,961.45 €133,870.01 -€4,909
Total QALYs 16.53 16.56 −0.03
ICER (€/QALY) - - €153,129

The base case results indicate that lebrikizumab was associated with lower total costs compared to dupilumab, resulting in cost savings of €4,909 per patient over the lifetime horizon. However, lebrikizumab was also associated with a slightly lower QALY gain (−0.03 QALYs) compared to dupilumab. There was no difference in life years gained (LYG) between the two treatments. The incremental cost-effectiveness ratio (ICER) for lebrikizumab compared to dupilumab was €153,129 per QALY mainly due to the very minor differences in QALYs.

To assess the robustness of the base case results, two scenario analyses were conducted. These analyses explored the impact of changes in key model parameters on the cost difference between lebrikizumab and dupilumab and are attached in the supplementary.

Detailed Cost Analysis

A comprehensive breakdown of costs by category provides insights into the main drivers of the cost difference between lebrikizumab and dupilumab (Table 4).

Table 4.

Detailed Cost Analysis by Category Over the Lifetime Horizon

Cost Category Lebrikizumab (€) Dupilumab (€) Incremental (€)
Drug acquisition (gross list price) €88,299 €93,647 -€5,349
Health state costs €39,596 €39,471 €125
Adverse event costs €314 €371 -€58
Flare costs €152 €150 €2
Other costs €601 €230 €370
Total costs €128,961 €133,870 -€4,909

The primary driver of the cost difference was drug acquisition costs, where lebrikizumab was €5,349 less costly than dupilumab over the lifetime horizon. The drug acquisition cost based on the health economic model. The total drug cost over the simulated lifetime vary depending on the parameters used (EASI75, IGA). This significant difference in drug costs was the main factor contributing to the overall cost savings associated with lebrikizumab.

Health state costs were slightly higher for lebrikizumab (+€125), which may reflect differences in the distribution of patients across health states over time. Adverse event costs were lower for lebrikizumab (-€58). Flare costs were similar between the two treatments, with lebrikizumab incurring only €2 more in flare-related expenses.

Cost Analysis by Health State

The distribution of QALYs across different health states provides insight into the effectiveness of each treatment in managing atopic dermatitis over time. Dupilumab accrued more QALYs in the response state (6.55 vs 6.43), indicating that patients on dupilumab spent more time in the state of treatment response. However, examining the distribution of costs across health states provides further insight into the economic impact of each treatment. In the response state, costs were lower for lebrikizumab (€8,055) compared to dupilumab (€8,171). This difference of €116 per patient in the response state suggests that even when patients achieve a response, the ongoing costs associated with lebrikizumab treatment are lower. Conversely, in the non-response state, costs were slightly higher for lebrikizumab (€31,541) compared to dupilumab (€31,299).

Scenario Analysis

In addition, there are two further scenarios to demonstrate the cost-effectiveness for Lebrikizumab compared to Dupilumab, adding the results in the supplements (Supplement A and B):

  1. Choice of endpoint used to define response - Clinical outcome of EASI-75. EASI-75 is the most used outcome measure according to European guidelines for AD. In the cost comparison for EASI 75 (only, not as proxy for the combined outcome EASI 50 + DLQI≥4), lebrikizumab was associated with smaller savings of €1,601 versus dupilumab, while the numerical QALY difference favoured dupilumab by 0.03 either.

  2. Choice of endpoint used to define response - Clinical outcome of IGA 0 or 1. This endpoint represents the main reimbursement anchor in the local healthcare system for AD treatment in Austria. In this case, dupilumab can show incremental cost-effectiveness savings in comparison to lebrikizumab in the amount of €3,147.

While the choice of any of the three clinical outcomes influences the cost-effectiveness analysis, lebrikizumab demonstrates potential cost savings with comparable effectiveness in 2 of 3 most relevant clinical outcomes compared to dupilumab.

Discussion

The present cost analysis provides valuable insights into the economic evaluation of lebrikizumab compared to dupilumab in the treatment of severe AD patients in Austria. The results indicate potential cost savings through the use of lebrikizumab with comparable clinical efficacy, as confirmed by previous studies,11,12,16 which is of great importance for both clinical practice and health policy decisions.

The analysis revealed that lebrikizumab could lead to a cost reduction of approximately 3.7% per patient per year compared to dupilumab. These savings primarily result from the lower drug costs of lebrikizumab. Silverberg et al,16 and Rand et al,12 confirmed in their indirect treatment comparison studies the comparable efficacy and safety of both biologics after the induction phase till week 16 and in the maintenance phase till week 52. The cost savings are particularly relevant considering rising healthcare expenditures and the need to identify efficient therapeutic options for chronic diseases such as AD.4

For healthcare decision-makers, the results provide a foundation for reimbursement decisions and resource allocation. The cost-efficiency of lebrikizumab meets the requirements of the Austrian legal pricing framework (§ 351c Abs. 9 ASVG) with a more favourable price and economical prescription. Lebrikizumab fulfils this criterion as it is more cost-effective than the available dupilumab while maintaining comparable efficacy. This is a crucial factor for the accessibility and availability of this innovative therapeutic option for patients with moderate-to-severe atopic dermatitis in Austria.

A key strength of this study lies in the use of a validated cost model from NICE appraisal enhances the reliability of the results. Moreover, the analysis is based on an adjusted comparative clinical data.

It is important to note that the model did not include a partial response state, as there were insufficient data for this category at the time of model development. The absence of a partial response state may impact the granularity of the QALY distribution and could potentially underestimate the benefits of treatments that achieve partial but clinically meaningful improvements in patients who do not meet the full response criteria. A further limitation of this study is the use of an indirect comparison, which is subject to the absence of direct controlled trials. Several limitations inherent to indirect treatment comparisons (ITCs) should be considered when interpreting these findings. The validity of any ITC depends on the assumption of transitivity, meaning that the included trials must be sufficiently similar in all factors that may modify the relative treatment effect, such as patient characteristics, disease severity, prior treatments, endpoint definitions, and duration of follow-up. Even when trials appear comparable, residual imbalances in known or unmeasured effect modifiers cannot be ruled out and may bias the results. Because randomization is preserved only within, not across, the individual trials, indirect estimates do not provide the same level of evidence as direct head-to-head comparisons. Where population-adjusted methods are applied, adjustment is limited to the covariates reported in published sources and reduces the effective sample size, which lowers precision. In addition, the absence of closed loops in sparse evidence networks prevents formal assessment of consistency between direct and indirect evidence, and summary measures such as hazard ratios rely on assumptions, such as proportional hazards, that may not hold. The authors of Mastorino et al,24 mentioned that dose-spacing of dupilumab may be feasible in selected patients with stable disease control, which represents an additional limitation of the model assumptions This dosing regimen could lead to lower drug acquisition costs for dupilumab and, therefore, could potentially lead to a different cost assessment compared to lebrikizumab. However, the number of dose spacing patients is uncertain. Additionally, the treatment-specific response-rate point estimates derived from the network meta-analysis and matched-adjusted indirect comparison were incorporated into the model as fixed inputs, without a probabilistic sensitivity analysis capturing their joint uncertainty. As these estimates were not statistically significantly different, but also not formally tested for equivalence, the resulting small numerical differences in modelled QALYs and health-state costs should be interpreted with corresponding caution.

The baseline scenario was confirmed by Scenario Analysis 1, and the cost savings indicate an advantage in favour of lebrikizumab. In Scenario Analysis 2, however, the result favours dupilumab. It should be noted that Scenario Analysis 2 is based on IGA 0/1 response status. As this represents a dichotomised outcome derived from an ordinal scale, it provides only a relatively coarse measure of treatment response and does not adequately capture the magnitude of proportional improvement. Furthermore, patient-relevant benefit cannot be directly inferred from IGA status alone.

Based on these results and the available literature, patients with severe AD and inadequate response to topical therapies could particularly benefit from lebrikizumab. Wollenberg et al4 emphasize the need for effective systemic therapies for this patient group.

These findings on lebrikizumab, indicate a potential numerical cost savings with comparable efficacy in treating severe atopic dermatitis (AD). Such economic advantages have crucial implications for clinical practice and health policy decisions, particularly in Austria. The heterogeneity of AD, as noted by Augustin et al,5 necessitates individualized therapeutic approaches, making lebrikizumab a valuable addition to treatment options. The reimbursement of lebrikizumab for patients in the Austrian public health care setting since January 1st, 2025, has improved access to a novel IL-13 biological treatment. This development, could optimize and ensure high-quality treatment while contributing to a more financially sustainable healthcare system for AD management.

Acknowledgment

The abstract of this paper was presented at the ISPOR Europe 2024 (Barcelona, Spain) as a poster presentation with interim findings. The poster’s abstract was published in “Poster Abstracts” in Value in Health: https://www.valueinhealthjournal.com/article/S1098−3015(24)03848−8/fulltext.

Funding Statement

This study and article were funded by Almirall S.A. Laia Solé-Feu and Bülent Akmaz are employees of Almirall S.A. Yannick Walzer is affiliated with MArS Market Access & Pricing Strategy GmbH, which was engaged by Almirall for this project, and Bernhard Schwarz conducted the Austrian model adaptation on behalf of Almirall.

Artificial Intelligence

For the preparation of individual text drafts, an internal, secured AI-assisted language model was used. All AI-generated content was reviewed repeatedly by the authors, revised, and adapted to the scientific context. The final intellectual content and linguistic formulation of the manuscript were determined by the authors, who assume full responsibility for its content. The AI tool used in this study was HealthMind (worked with the offline model Llama-3.1-8B-Instruct), provided by MArS Market Access & Pricing Strategy GmbH.

Data Sharing Statement

The model was developed by the authors using inputs from publicly available sources, including published literature and NICE documentation. The source data are cited within the article.

Ethic Declaration

This study is a cost-effectiveness analysis using published, aggregated clinical, cost and utility data. As no patients were involved and no individual data were processed, no ethics committee review was required, consistent with standard practice for model-based health-economic analysis.

Disclosure

The authors report no conflicts of interest in this work.

References

  • 1.Chernyshov PV, Tomas-Aragones L, Manolache L, et al. Quality of life measurement in atopic dermatitis. Position paper of the European Academy of Dermatology and Venereology (EADV) Task Force on quality of life. J Eur Acad Dermatol Venereol. 2017;31(4):576–10. doi: 10.1111/jdv.14058 [DOI] [PubMed] [Google Scholar]
  • 2.Vakharia PP, Chopra R, Sacotte R, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol. 2017;119(6):548–52.e3. doi: 10.1016/j.anai.2017.09.076 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080–1091. doi: 10.1056/NEJMoa2206714 [DOI] [PubMed] [Google Scholar]
  • 4.Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–878. doi: 10.1111/jdv.14888 [DOI] [PubMed] [Google Scholar]
  • 5.Augustin M, Langenbruch A, Blome C, et al. Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. J Eur Acad Dermatol Venereol. 2020;34(1):142–152. doi: 10.1111/jdv.15919 [DOI] [PubMed] [Google Scholar]
  • 6.Working Association of Scientific Medical Associations e. V. (AWMF). S3 Leitlinie - Atopische Dermatitis (AD) [Neurodermitis; atopisches Ekzem] AWMF-Register-Nr. 013-027, 2023. Available from: https://register.awmf.org/assets/guidelines/013-027l_S3_Atopische-Dermatitis-AD-Neurodermitis-atopisches-Ekzem_2024-01.pdf. Accessed October 25, 2026.
  • 7.Darbellay B, Huber M, Bisschoff IJ, et al. Real-world burden of atopic dermatitis: Austrian and Swiss data from the MEASURE-AD study. J Dermatological Treat. 2024;35(1):2415407. doi: 10.1080/09546634.2024.2415407 [DOI] [PubMed] [Google Scholar]
  • 8.Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020 [DOI] [PubMed] [Google Scholar]
  • 9.Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA dermatol. 2023;159(2):182–191. doi: 10.1001/jamadermatol.2022.5534 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Pereyra-Rodriguez J-J, Alcantara-Luna S, Domínguez-Cruz J, et al. Short-term effectiveness and safety of biologics and small molecule drugs for moderate to severe atopic dermatitis: a systematic review and network meta-analysis. Life. 2021;11(9):927. doi: 10.3390/life11090927 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Drucker AM, Lam M, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update. JAMA dermatol. 2024;160(9):936–944. doi: 10.1001/jamadermatol.2024.2192 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Rand K, Ramos-Goñi JM, Akmaz B, Solé-Feu L, Armario-Hita J-C. Matching-adjusted indirect comparison of the long-term efficacy maintenance and adverse event rates of lebrikizumab versus dupilumab in moderate-to-severe atopic dermatitis. Dermatol Ther. 2024;14(1):169–182. doi: 10.1007/s13555-023-01058-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Allgemeines Sozialversicherungsgesetz (ASVG). Abschnitt V - Erstattungskodex 351c- Aufnahme von Arzneispezialitäten in den Erstattungskodex 2026. Available from: https://www.ris.bka.gv.at/NormDokument.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10008147&Artikel=&Paragraf=351c&Anlage=&Uebergangsrecht=. Accessed October 25, 2026.
  • 14.National Institute for Health and Care Excellence (NICE). Technology Appraisals: lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over London: National Institute for Health and Care Excellence (NICE)©; 2024. Available from: https://www.nice.org.uk/guidance/ta986/resources/lebrikizumab-for-treating-moderate-to-severe-atopic-dermatitis-in-people-12-years-and-over-pdf-82615913759941. Accessed October 25, 2026. [PubMed] [Google Scholar]
  • 15.Scottish Medicines Consortium (SMC). Medicines advice: lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over 2024. Available from: https://scottishmedicines.org.uk/medicines-advice/lebrikizumab-ebglyss-full-smc2707/. Accessed October 25, 2026.
  • 16.Silverberg JI, Bieber T, Paller AS, et al. Lebrikizumab vs other systemic monotherapies for moderate-to-severe atopic dermatitis: network meta-analysis of efficacy. Dermatol Ther. 2025;15(3):615–633. doi: 10.1007/s13555-025-01357-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168. doi: 10.1016/S0140-6736(21)00588-2 [DOI] [PubMed] [Google Scholar]
  • 18.National Institute for Health and Care Excellence (NICE). Baricitinib for treating moderate to severe atopic dermatitis. Technology Appraisal Guidance Reference Number: TA681. 2021. Available from. https://www.nice.org.uk/guidance/ta681/resources/baricitinib-for-treating-moderate-to-severe-atopic-dermatitis-pdf-82609375014853. Accessed August 1, 2026 [PubMed]
  • 19.Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–2181. doi: 10.1016/S0140-6736(21)00589-4 [DOI] [PubMed] [Google Scholar]
  • 20.National Institute for Health and Care Excellence (NICE). Dupilumab for treating moderate to severe atopic dermatitis. Technology appraisal guidance. Reference number: TA534 Published. 2018. Available from https://www.nice.org.uk/guidance/ta534/resources/dupilumab-for-treating-moderate-to-severe-atopic-dermatitis-pdf-82606900940485. Accessed August 1, 2026. [PubMed]
  • 21.National Institute for Health and Care Excellence (NICE). Final draft guidance: lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over 2024. Available from: https://www.nice.org.uk/guidance/ta986/documents/674. Accessed October 25, 2026. [PubMed]
  • 22.Dachverband der österreichischen Sozialversicherung. Erstattungskodex - EKO, Stand 1. 2026. Accessed January 1, 2026.
  • 23.Dachverband der österreichischen Sozialversicherung. Verfahrensordnung zur Herausgabe des Erstattungskodex nach § 351g ASVG. VO-EKO. 2020. Available from. https://ris.bka.gv.at/Dokumente/Avsv/AVSV_2020_0040/AVSV_2020_0040.pdf. Accessed August 1, 2026. [Google Scholar]
  • 24.Mastorino L, Borrelli R, Macagno N, et al. Therapeutic modulation of dupilumab in patients with severe atopic dermatitis: clinical effectiveness in real life. Dermatitis. 2024;35(6):625–635. doi: 10.1089/derm.2024.0146 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The model was developed by the authors using inputs from publicly available sources, including published literature and NICE documentation. The source data are cited within the article.


Articles from ClinicoEconomics and Outcomes Research: CEOR are provided here courtesy of Dove Press

RESOURCES